Premium
Intralesional BCG in the treatment of metastatic malignant melanoma
Author(s) -
Mastrangelo Michael J.,
Sulit Hector L.,
Prehn Liisa Melartin,
Bornstein Richard S.,
Yarbro John W.,
Prehn Richmond T.
Publication year - 1976
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197602)37:2<684::aid-cncr2820370212>3.0.co;2-y
Subject(s) - medicine , melanoma , metastatic melanoma , disease , therapeutic effect , oncology , gastroenterology , surgery , cancer research
The therapeutic efficacy of intralesional BCG (Bacillus Calmette‐Guerin; one immunizing dose every 2 weeks for a minimum of five treatments) was studied in 19 melanoma patients. Of 15 patients evaluable for response, five experienced significant objective improvement (two complete and three partial remissions). Objective improvement was limited to those patients with dermal metastatic disease. In vitro cytotoxicity in the presence of patient's serum bore, on average, a relationship to the clinical disease. In certain individual cases, serum blocking and/or lymphocyte stimulation may have had prognostic significance.